Nephros Inc 8-K Filing
Ticker: NEPH · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1196298
| Field | Detail |
|---|---|
| Company | Nephros Inc (NEPH) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Nephros Inc (ticker: NEPH) to the SEC on Nov 26, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common stock, $0.001 par value NEPH The Nasdaq Stock Mar).
How long is this filing?
Nephros Inc's 8-K filing is 3 pages with approximately 810 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2025-11-26 16:15:32
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value NEPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-25-025155.txt ( ) — 194KB
- neph-20251121.xsd (EX-101.SCH) — 3KB
- neph-20251121_lab.xml (EX-101.LAB) — 33KB
- neph-20251121_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On November 21, 2025, Nephros, Inc. (the "Company") entered into a license and supply agreement (the "License and Supply Agreement") with Medica S.p.A. ("Medica"), an Italy-based medical product manufacturing company, for the marketing and sale of certain filtration products based upon Medica's proprietary Medisulfone ultrafiltration technology in conjunction with the Company's filtration products (collectively, the "Products"), and to engage in an exclusive supply arrangement for the Products. The License and Supply Agreement supersedes and replaces that certain License and Supply Agreement, dated December 11, 2023 (the "Prior Agreement"), between the Company and Medica, which Prior Agreement was terminated by the parties upon entry into the License and Supply Agreement. Under the License and Supply Agreement, Medica granted the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the Products in the Territory (as defined in the License and Supply Agreement). In addition, the Company granted to Medica an exclusive license under the Company's intellectual property to make the Products during the term of the License and Supply Agreement. In exchange for the rights granted, the Company has agreed to make minimum annual aggregate purchases from Medica of 4,976,000, 5,349,000, 5,750,000, 6,000,000 and 6,300,000 for the years 2026, 2027, 2028, 2029 and 2030, respectively. The License and Supply Agreement contains other customary representations and warranties and indemnification obligations of the parties. The term of the License and Supply Agreement continues in effect through December 31, 2030, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement. The Company has the right to terminate the License and Supply Agreement for convenience upon 90 days' prior written notice. Medica may terminate the Lice
02. Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement. The information related to the termination of the Prior Agreement contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Nephros, Inc. Dated: November 26, 2025 By: /s/ Judy Krandel Judy Krandel Chief Financial Officer